Parallel Advisors’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $122K | Buy |
704
+40
| +6% | +$7.42K | ﹤0.01% | 1471 |
|
|
2025
Q4 | $133K | Buy |
664
+35
| +6% | +$6.35K | ﹤0.01% | 1307 |
|
|
2025
Q3 | $98.5K | Buy |
629
+17
| +3% | +$2.7K | ﹤0.01% | 1427 |
|
|
2025
Q2 | $92.8K | Buy |
612
+138
| +29% | +$18.4K | ﹤0.01% | 1396 |
|
|
2025
Q1 | $71.4K | Buy |
474
+216
| +84% | +$36.2K | ﹤0.01% | 1441 |
|
|
2024
Q4 | $47.6K | Buy |
258
+82
| +47% | +$15.8K | ﹤0.01% | 1666 |
|
|
2024
Q3 | $34.7K | Buy |
176
+10
| +6% | +$2.08K | ﹤0.01% | 1809 |
|
|
2024
Q2 | $34.3K | Sell |
166
-19
| -10% | -$4.3K | ﹤0.01% | 1713 |
|
|
2024
Q1 | $50.1K | Buy |
185
+19
| +11% | +$4.54K | ﹤0.01% | 1497 |
|
|
2023
Q4 | $39.2K | Sell |
166
-59
| -26% | -$11.6K | ﹤0.01% | 1556 |
|
|
2023
Q3 | $44.1K | Buy |
225
+30
| +15% | +$6.16K | ﹤0.01% | 1453 |
|
|
2023
Q2 | $41K | Buy |
195
+28
| +17% | +$5.57K | ﹤0.01% | 1499 |
|
|
2023
Q1 | $33.7K | Sell |
167
-19
| -10% | -$4.31K | ﹤0.01% | 1578 |
|
|
2022
Q4 | $40.5K | Sell |
186
-17
| -8% | -$3.71K | ﹤0.01% | 1367 |
|
|
2022
Q3 | $40K | Buy |
203
+4
| +2% | +$864 | ﹤0.01% | 1351 |
|
|
2022
Q2 | $43K | Buy |
199
+25
| +14% | +$6.11K | ﹤0.01% | 1322 |
|
|
2022
Q1 | $50K | Sell |
174
-89
| -34% | -$27.4K | ﹤0.01% | 1284 |
|
|
2021
Q4 | $99K | Sell |
263
-52
| -17% | -$20.2K | ﹤0.01% | 1018 |
|
|
2021
Q3 | $130K | Buy |
315
+75
| +31% | +$31.1K | 0.01% | 874 |
|
|
2021
Q2 | $89K | Buy |
240
+66
| +38% | +$22K | ﹤0.01% | 989 |
|
|
2021
Q1 | $50K | Buy |
174
+46
| +36% | +$12.8K | ﹤0.01% | 1182 |
|
|
2020
Q4 | $32K | Sell |
128
-42
| -25% | -$10K | ﹤0.01% | 1281 |
|
|
2020
Q3 | $38K | Hold |
170
| – | – | ﹤0.01% | 1174 |
|
|
2020
Q2 | $29K | Sell |
170
-6
| -3% | -$958 | ﹤0.01% | 1258 |
|
|
2020
Q1 | $22K | Sell |
176
-28
| -14% | -$4.2K | ﹤0.01% | 1269 |
|
|
2019
Q4 | $31K | Sell |
204
-3
| -1% | -$415 | ﹤0.01% | 1209 |
|
|
2019
Q3 | $27K | Buy |
207
+23
| +13% | +$3.08K | ﹤0.01% | 1221 |
|
|
2019
Q2 | $26K | Sell |
184
-32
| -15% | -$4.34K | ﹤0.01% | 1155 |
|
|
2019
Q1 | $31K | Hold |
216
| – | – | ﹤0.01% | 1043 |
|
|
2018
Q4 | $24K | Hold |
216
| – | – | ﹤0.01% | 987 |
|
|
2018
Q3 | $29K | Hold |
216
| – | – | ﹤0.01% | 1011 |
|
|
2018
Q2 | $24K | Hold |
216
| – | – | ﹤0.01% | 980 |
|
|
2018
Q1 | $23K | Hold |
216
| – | – | ﹤0.01% | 953 |
|
|
2017
Q4 | $24K | Hold |
216
| – | – | ﹤0.01% | 945 |
|
|
2017
Q3 | $22K | Hold |
216
| – | – | ﹤0.01% | 960 |
|
|
2017
Q2 | $21K | Buy |
216
+81
| +60% | +$7.46K | ﹤0.01% | 984 |
|
|
2017
Q1 | $12K | Buy |
135
+45
| +50% | +$3.82K | ﹤0.01% | 1135 |
|
|
2016
Q4 | $7K | Buy |
+90
| New | +$6.83K | ﹤0.01% | 1228 |
|
Other funds holding CRL
VCM
VPM
Parallel Advisors's CRL Position: Q1 2026 in Review
Parallel Advisors increased its Charles River Laboratories (CRL) stake by 6% in Q1 2026, buying an estimated $7.42K and bringing the position to 704 shares worth $122K. The position accounts for ﹤0.01% of the portfolio, ranked #1471.
Parallel Advisors first reported a position in CRL in Q4 2016 and has held it in 38 quarters since. The position peaked at $133K in Q4 2025. 557 funds tracked by Wall St. Rank hold CRL as of Q1 2026.
- Parallel Advisors held 704 shares of Charles River Laboratories worth $122K as of Q1 2026.
- Parallel Advisors bought 40 Charles River Laboratories shares in Q1 2026, an estimated $7.42K.
- Charles River Laboratories made up ﹤0.01% of Parallel Advisors's portfolio in Q1 2026, its #1471 holding.
- Parallel Advisors first reported a position in Charles River Laboratories in Q4 2016 and has held it in 38 quarters since.
- Parallel Advisors's Charles River Laboratories position peaked at $133K in Q4 2025.
- 557 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.
Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.